|
|
||||||||
Male Reproductive Tract |
Institut National de la Santé et de la Recherche Médicale (INSERM U 407),3 Faculté de Médecine Lyon-Sud, 69921, Oullins, France
Biochemistry Laboratory,4 University-Hospital Sahloul, Sousse, Tunisia
Although the apoptotic cell death process in the prostate is known to be under the control of androgens, the key components targeted by the hormones remain to be investigated. In the present study, we report that the expression and the activation of the effector caspases-3 and -6 are under the control of testosterone in the adult rat ventral prostate. By using a model of adult castrated rats supplemented (or not) with androgens, we observed an increase in caspase-3 (3-fold) and -6 (4-fold) mRNA (P < 0.0001) and procaspase-3 (32 kDa) and -6 (34 kDa) protein levels by 3 days and 1 wk, respectively, after castration in the ventral prostate. Castration also induced an increase in the activation of the procaspases in the ventral prostate, since active (cleaved) caspase-3 (17 kDa) and -6 (12 kDa) forms reached maximal levels by 1 wk after castration. Testosterone administration to castrated adult rats prevented the increase in caspase-3 and -6 mRNA as well as in procaspase-3 and -6 and active caspase-3 and -6 levels in the ventral prostate lobe. In contrast, no changes were observed in the initiator caspase-8 mRNA and protein (procaspase and active) levels after castration. No changes in caspase-3 and -6 expression and activation were observed in the dorsolateral and anterior prostate lobes after castration and testosterone supplementation. Together, the present results show that testosterone inhibits apoptosis in the ventral prostate by potentially targeting the transcriptional activity of effector caspase-3 and -6 genes (but not of casapase-8 gene) as well as the cleavage of procaspase-3 and -6 into active enzymes.
2 Correspondence: Mohamed Benahmed, INSERM U.407, Communications cellulaires en biologie de la reproduction, Faculté de Médecine Lyon-Sud, 165 chemin du grand Revoyet, BP 12, 69921 Oullins Cedex, France. FAX: 33 4 78 86 31 16; benahmed{at}grisn.univ-lyon1.fr
This article has been cited by other articles:
![]() |
R. Snoek, H. Cheng, K. Margiotti, L. A. Wafa, C. A. Wong, E. C. Wong, L. Fazli, C. C. Nelson, M. E. Gleave, and P. S. Rennie In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors Clin. Cancer Res., January 1, 2009; 15(1): 39 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Potter, M. G. Zager, and H. A. Barton Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E952 - E964. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Morimoto, C A Mendoza-Rodriguez, M Hiriart, M E Larrieta, P Vital, and M A Cerbon Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas J. Endocrinol., November 1, 2005; 187(2): 217 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Rudmann, I. R. Cohen, M. R. Robbins, D. E. Coutant, and J. W. Henck Androgen Dependent Mammary Gland Virilism in Rats Given the Selective Estrogen Receptor Modulator LY2066948 Hydrochloride Toxicol Pathol, October 1, 2005; 33(6): 711 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Desai, A. M. Michalowska, P. Kondaiah, J. M. Ward, J. H. Shih, and J. E. Green Gene Expression Profiling Identifies a Unique Androgen-Mediated Inflammatory/Immune Signature and a PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10)-Mediated Apoptotic Response Specific to the Rat Ventral Prostate Mol. Endocrinol., December 1, 2004; 18(12): 2895 - 2907. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Carey, L. M. Sasur, H. Kawakubo, V. Gupta, B. Christian, P. M. Bailey, and S. Maheswaran Mutually Antagonistic Effects of Androgen and Activin in the Regulation of Prostate Cancer Cell Growth Mol. Endocrinol., March 1, 2004; 18(3): 696 - 707. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |